Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400959 | 0.91 | TACR1 (0.61) | TACR1SIGMAR1BCHEACHEBACE1 | |
| SCHEMBL6439506 | 0.88 | TACR1 (0.54) | TACR1SIGMAR1BCHEACHEBACE1 | |
| SCHEMBL6440867 | 0.88 | TACR1 (0.65) | TACR1SIGMAR1BCHEACHEBACE1 | |
| SCHEMBL3902021 | 0.85 | TACR1 (0.54) | TACR1SIGMAR1ALDH1A1 | |
| SCHEMBL3997201 | 0.85 | TACR1 (0.52) | TACR1SIGMAR1ESR1ESR2 | |
| SCHEMBL1916289 | 0.83 | TACR1 (0.51) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1617419 | 0.82 | TACR1 (0.50) | TACR1SIGMAR1DRD4ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL3290339 | 0.82 | TACR1 (0.52) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1617423 | 0.81 | TACR1 (0.56) | TACR1SIGMAR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6413713 | 0.78 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1229373-C | Piperidinee derivatives as neurokinin/antagonists | HOFFMANN LA ROCHE (CH) | 2005-11-30 | — | — | CN | disclosed |
| EP-1360184-B1 | PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| CN-1491222-A | piperidine derivatives as neurokinin 1 antagonists | - | 2004-04-21 | — | — | CN | disclosed |
| EP-1360184-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-12 | — | — | EP | disclosed |
| US-6642226-B2 | Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062784-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | TACR1, OPRK1, TACR2 | TACR1 1/4885SIGMAR1 27/4885BCHE 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.